Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Dmi Research

Neither a doctor nor a teaching hospital

Research payments

$664,588

345 payments

Through program year 2025, Dmi Research is reported as receiving $664,588 in research payments, across 345 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $4,818 1
2024 Research $10,689 5
2023 Research $17,627 11
2022 Research $385,552 170
2021 Research $40,138 18
2020 Research $198,405 139
2019 Research $7,358 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Endo Pharmaceuticals Inc. $367,421 56 payments
  2. Ironwood Pharmaceuticals, Inc $200,650 39 payments
  3. Novo Nordisk AS $62,065 237 payments
  4. Horizon Therapeutics plc $23,159 2 payments
  5. Sage Therapeutics, Inc. $7,000 1 payment
  6. Biohaven Pharmaceuticals, Inc. $2,547 5 payments
  7. Biohaven Pharmaceutical Holding Company Ltd. $1,745 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis $273,740 43 payments
  2. C3718-301 $200,650 39 payments
  3. A Multi-Center, Open-Label, Extension Study to Evaluate the Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis $93,681 13 payments
  4. Nn9535-4533 $62,065 237 payments
  5. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa? (Pegloticase) (Mirror Randomized Controlled Trial [RCT]) $15,801 1 payment
  6. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa Pegloticase Mirror Randomized Controlled Trial RCT $7,358 1 payment
  7. A Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Brexanolone in the Treatment of Adolescent Female Subjects With Postpartum Depression $7,000 1 payment
  8. A Randomized Double-Blind Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder $4,292 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record